MSI and or dMMR
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. (NCT04006262) | GERCOR - Multidisciplinary Oncology Cooperative Group | 2019-10-23 |
Track MSI and or dMMR automatically
Every clearance here is in the API, with alerts when new ones post.